Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UCHL1 divergent transcript (UCHL1-DT), also called UCHL1 antisense RNA 1 (UCHL1-AS1), is a long non-coding RNA transcribed from the opposite DNA strand of the UCHL1 gene in a head-to-head configuration and overlaps with the 5' region of UCHL1 mRNA[1][3][4][9]. UCHL1-DT functions as a natural antisense lncRNA and is the founding member of the SINEUP family, which increase translation of their sense mRNA targets via a combination of an RNA binding domain (overlapping the target) and an effector domain (inverted SINEB2 sequence). In neurons, UCHL1-DT is regulated by the Nurr1 transcription factor and plays a role in neuronal homeostasis, with evidence for downregulation in neurodegenerative disease models such as Parkinson’s disease. Unlike protein-coding genes, UCHL1-DT itself is not a direct drug target but is of significant research interest for its regulatory role in gene expression and potential for RNA-based gene therapy[1][3][4][9].
SINEUP lncRNA: SINEUPs are a class of antisense lncRNAs that enhance translation of their sense transcript, here increasing UCHL1 protein production
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UCHL1 divergent transcript (UCHL1-DT).